Jiangsu Nhwa Pharmaceutical (002262.SZ) Earnings Analysis
Jiangsu Nhwa Pharmaceutical (002262.SZ) next reports earnings on 2026-08-18, consensus EPS 0.37 CNY. Last quarter (2026-04-20) it missed with EPS 0.31 CNY vs 0.47 CNY est (-34%). It has beaten estimates in 0/5 recent quarters (0%). Trailing P/E 20.52.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 002262.SZ next report earnings?
| Next earnings date | 2026-08-18 |
|---|---|
| Consensus EPS estimate | 0.37 CNY |
| Revenue estimate | 1.58B |
002262.SZ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-20 | 0.31 CNY | 0.47 CNY | -34% | Miss |
| 2026-04-17 | -0.0484 CNY | 0.21 CNY | -123% | Miss |
| 2025-10-24 | 0.4 CNY | 0.42 CNY | -4.8% | Miss |
| 2025-04-18 | 0.3 CNY | 0.31 CNY | -3.2% | Miss |
| 2024-10-25 | 0.39 CNY | 0.41 CNY | -4.9% | Miss |
Beat rate: 0/5 (0%) over reported quarters with consensus data.
002262.SZ valuation and analyst view
| Trailing P/E | 20.52 |
|---|---|
| Trailing EPS | 1.064 CNY |
| Price / book | 2.63 |
| Dividend yield | 1.84% |
| Market cap | 22.02B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Jiangsu Nhwa Pharmaceutical (002262.SZ)'s next earnings date?
Jiangsu Nhwa Pharmaceutical is next scheduled to report on 2026-08-18, with a consensus EPS estimate of 0.37 CNY and revenue estimate of 1.58B.
Did 002262.SZ beat earnings last quarter?
In its 2026-04-20 report, 002262.SZ posted EPS of 0.31 CNY versus a 0.47 CNY estimate — a miss of 34%.
What is 002262.SZ's earnings track record?
Over the last 5 reported quarters with consensus data, 002262.SZ beat estimates 0 times (0%).
What is 002262.SZ's current P/E ratio and EPS?
002262.SZ trades at a trailing P/E of 20.52 on trailing EPS of 1.0635637573474923 CNY.
What do analysts rate 002262.SZ?
002262.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.